Nuvectis Pharma, Inc. (NVCT) Balance Sheet
As of 2026-06-30 (10-Q), Nuvectis Pharma, Inc. (NVCT) reported total assets of $22.4M, total liabilities of $13.3M and shareholders' equity of $9.1M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $22.2M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NVCTNuvectis Pharma, Inc.Follow NVCT — free
—
Price chart with a free account
- Market cap
- 653.3M
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 10 Nov, in 16 days
| Line | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|
| Cash and equivalents | 20.0 | 19.1 | 18.5 | 31.6 | 22.2 | |
| Current assets | 20.4 | 19.2 | 18.6 | 31.7 | 22.4 | |
| Total assets | 20.4 | 19.2 | 18.6 | 31.7 | 22.4 | |
| Current liabilities | 6.2 | 7.0 | 8.9 | 13.3 | 13.3 | |
| Total liabilities | 6.2 | 7.0 | 8.9 | 13.3 | 13.3 | |
| Shareholders' equity | 14.2 | 12.2 | 9.7 | 18.4 | 9.1 |
USD millions · SEC XBRL
Nuvectis Pharma, Inc. — questions
- How much cash does Nuvectis Pharma, Inc. have?
- $22.2M in cash and cash equivalents as of 2026-06-30.
- What are Nuvectis Pharma, Inc.'s total assets?
- $22.4M as of 2026-06-30.
- What is Nuvectis Pharma, Inc.'s shareholders' equity?
- $9.1M as of 2026-06-30.
Every figure on this page comes from Nuvectis Pharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.